scholarly journals Long noncoding RNA AFAP1-AS1, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis

2016 ◽  
Vol Volume 9 ◽  
pp. 4247-4254 ◽  
Author(s):  
Hong-liang Luo ◽  
Qi-zhen Xue ◽  
Pei-qian Zhu ◽  
Yi Zhang ◽  
Fang-teng Liu ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Meta Analysis

scholarly journals Long noncoding RNA MEG3, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (12) ◽  
pp. 19049-19056 ◽  
Author(s):  
Xiangrong Cui ◽  
Xuan Jing ◽  
Chunlan Long ◽  
Jie Tian ◽  
Jing Zhu
Keyword(s):  
Clinical Outcome ◽  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Meta Analysis

scholarly journals Long Noncoding RNA CCAT2 as a Potential Novel Biomarker to Predict the Clinical Outcome of Cancer Patients: A Meta-Analysis

2017 ◽  
Vol 8 (8) ◽  
pp. 1498-1506 ◽  
Author(s):  
Juan Tan ◽  
Yi-Chao Hou ◽  
Lin-Na Fu ◽  
Yun-Qian Wang ◽  
Qian-Qian Liu ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Meta Analysis

scholarly journals Prognostic role of long noncoding RNA ZFAS1 in cancer patients: a systematic review and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (59) ◽  
pp. 100490-100498 ◽  
Author(s):  
Tian Lan ◽  
Xiong Lan ◽  
Guangcai Li ◽  
Zhen Zheng ◽  
Minghua Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Meta Analysis ◽  
Prognostic Role

scholarly journals Long noncoding RNA UCA1 as a novel biomarker of lymph node metastasis and prognosis in human cancer: a meta-analysis

2019 ◽  
Vol 39 (4) ◽  
Author(s):  
Congmin Liu ◽  
Jing Jin ◽  
Jin Shi ◽  
Liqun Wang ◽  
Zhaoyu Gao ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Hot Spot ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Node Metastasis ◽  
Increased Risk

AbstractBackground: Urothelial carcinoma associated 1 (UCA1), a novel long noncoding RNA (lncRNA) which is first discovered in 2006 in human bladder cancer and has become a hot spot in recent years. UCA1 has been demonstrated correlated with clinical outcomes in various cancers. However, the results from each study are insufficient and not completely consistent. Therefore, we perform a systematic meta-analysis to evaluate the value for a feasible biomarker for metastasis and prognosis of cancer. Methods: Relevant English literatures were searched in PubMed, Cochrane Library, Web of science, Embase databases and Chinese literatures were searched in Chinese National Knowledge Infrastructure Wanfang from inception up to 17 April 2018. The pooled odds ratio (OR) and hazard ratio (HR) with 95% confidence interval (CI) using random/fixed-effect were used to identify the relationship between UCA1 and lymph node metastasis (LNM) or overall survival (OS) of cancer patients. Subgroup analysis and sensitivity analysis were performed. The current meta-analysis was performed using Review Manager 5.3 and Stata 12.0 software. Results: A total of 3411 patients from 38 studies were finally included. Patients who with high UCA1 expression suffered from an increased risk of LNM (OR = 2.50; 95% CI: 1.93–3.25). UCA1 was also significantly associated with OS (HR = 2.05; 95% CI: 1.77–2.38). Subgroup analyses across several different variables also showed the similar results in LNM and OS of cancer patients. Conclusion: High expression of UCA1 was linked with poor clinical outcome. UCA1 can serve as a potential molecular marker for metastasis and prognosis in different types of cancers.

scholarly journals Prognostic Value of Long Noncoding RNA SPRY4-IT1 on Survival Outcomes in Human Carcinomas: A Systematic Review and Meta-Analysis with TCGA Database

2020 ◽  
Vol 2020 ◽  
pp. 1-14
Author(s):  
Hai-mei Wang ◽  
Hui-jie Li ◽  
Jun-zhen Chen ◽  
Ke Pei ◽  
Qian Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Meta Analysis ◽  
Cancer Prognosis ◽  
Survival Outcomes ◽  
Human Cancers ◽  
Human Carcinomas ◽  
Tcga Dataset

Background. Emerging evidences have shown that long noncoding RNA SPRY4-IT1 can be aberrantly expressed in human cancers, and it could be an unfavorable prognostic factor in cancer patients. However, the prognostic mechanism of SPRY4-IT1 is still unclear. This study is aimed at evaluating its potential predictive value for cancer prognosis. Methods. We thoroughly searched PubMed, Embase, Web of Science, and MEDLINE databases so as to explore the relationship between SPRY4-IT1 expression and cancer prognosis value. Then, TCGA datasets were used to validate the results of our meta-analysis. Results. In all, seventeen studies involving 1650 patients were included in this meta-analysis. Pooled results showed that high expression of SPRY4-IT1 was significantly correlated with poor OS ( HR = 1.96 , 95% confidence interval CI = 1.47 ‐ 2.62 , P < 0.001 ) in cancer patients. Furthermore, exploration of TCGA dataset further validated that SPRY4-IT1 was aberrantly expressed in various cancers, which partially confirmed our results in this meta-analysis. Conclusions. The present systematic review and meta-analysis implicated that the aberrant expressions of lncRNA SPRY4-IT1 were strongly associated with clinical survival outcomes in various cancers and therefore might serve as a promising biomarker for predicting prognosis of human cancers.

scholarly journals Clinicopathological and Prognostic Role of Long Noncoding RNA Linc00152 in Various Human Neoplasms: Evidence from Meta-Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Chenkui Miao ◽  
Kai Zhao ◽  
Jundong Zhu ◽  
Chao Liang ◽  
Aiming Xu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Multiple Tumor ◽  
Multiple Neoplasms ◽  
Poor Outcomes ◽  
The Cochrane Library

Recent researches have demonstrated that long noncoding RNA linc00152 was aberrantly upregulated in multiple tumor types. High expression of linc00152 was associated with poor outcomes in cancer patients. Therefore, we conducted this meta-analysis to evaluate its potential value as a prognostic predictor in various human neoplasms. Eligible studies were searched through several electronic databases including PubMed, Embase, Web of Science, and the Cochrane Library. Eight original studies including 752 cancer patients were ultimately enrolled. Statistical analysis suggested that overexpression of linc00152 was significantly correlated with unfavorable overall survival (OS) (HR = 2.05, 95% CI: 1.59–2.64) and disease-free/progression-free survival (DFS/PFS) (HR = 3.52, 95% CI: 1.82–6.79) in cancer patients. In addition, a significant correlation was observed between aberrant linc000152 expression and lymph node metastasis (LNM) (OR = 2.49, 95% CI: 1.57–3.94) but not in vessel invasion (VI) (OR = 1.02, 95% CI: 0.54–1.93) and distant metastasis (DM) (OR = 0.600, 95% CI: 0.213–1.689). Our meta-analysis demonstrated that high linc00152 expression significantly predicted inferior OS and DFS/PFS in multiple neoplasms, as well as advanced LNM and VI. Linc00152 may serve as a potential indicator in predicting poor outcomes and metastases of diverse cancers.

scholarly journals Prognostic Value of Long Noncoding RNA SNHG12 in Various Carcinomas: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Zhi-Ran Li ◽  
Qin Yang ◽  
Tao Zhou ◽  
Yan-Hua Huang ◽  
Hua-Zhu Zhang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Prognostic Value ◽  
Bioinformatics Analysis ◽  
Meta Analysis ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Multiple Cancers

Background. Numerous recent studies suggested that overexpression of the long noncoding RNA small nucleolar RNA host gene 12 (SNHG12) exhibited prooncogenic activity in multiple cancers. However, results regarding the prognostic value of SNHG12 in cancers still remained controversial. Therefore, we conducted a meta-analysis complemented with bioinformatics analysis to elucidate the clinical significance of SNHG12 in cancer patients. Methods. PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang, and Weipu databases were searched for eligible studies until July 2020. Additionally, bioinformatics analysis was applied to verify the results of meta-analysis. Results. Twenty-three related studies consisting of 1389 cancer patients were enrolled in the current meta-analysis. Elevated SNHG12 expression was found to be significantly associated with poor overall survival (OS) ( HR = 1.81 ; 95% CI: 1.53-2.13; P < 0.001 ) and disease-free survival (DFS) ( HR = 1.40 ; 95% CI: 1.12-1.76; P = 0.004 ) in multiple cancers, which were also verified by the results of bioinformatics analysis. Moreover, overexpression of SNHG12 was also related to clinicopathological characteristics including LNM, distant metastasis, high clinical stage, large tumor size, and poor tumor differentiation in diverse types of cancers. Conclusion. The present findings indicated that SNHG12 might act as a novel biomarker for diagnosis or prognosis in human cancers.

scholarly journals High Expression of the Long Noncoding RNA SNHG15 in Cancer Tissue Samples Predicts an Unfavorable Prognosis of Cancer Patients: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-14 ◽  
Author(s):  
Cheng Zhang ◽  
Yang Ke ◽  
Xin Liu ◽  
Xinghong Wang ◽  
Yuehua Li ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Meta Analysis ◽  
Tnm Stage ◽  
High Expression ◽  
Cochrane Library ◽  
Clinicopathological Parameters ◽  
Cancer Tissue ◽  
Tissue Samples

Background. Although the prognostic value of lncRNA small nucleolar RNA host gene 15 (SNHG15) expression in cancers has been evaluated in many studies, the results remain controversial. This meta-analysis aimed to clarify the role of SNHG15 in the prognosis of different cancer patients. Materials and Methods. Eligible studies were selected from PubMed, PMC, EMBASE, Web of Science, and Cochrane Library according to the inclusion and exclusion criteria (up to December 20, 2019). The primary outcome was overall survival (OS) and recurrence-free survival (RFS). The secondary outcome was other clinicopathological parameters (including advanced TNM stage, lymph node metastasis, distant metastases, and gender). The Cancer Genome Atlas (TCGA) dataset was used to verify the analysis results. Results. Eleven eligible studies were eventually included, involving 9 different types of cancer and 1,079 patients. The high expression of SNHG15 was indicative of a significantly poor OS of cancer patients (HR = 1.96, 95% CI = 1.55–2.47, P<0.00001). Subgroup analysis showed that the high expression of SNHG15 was associated with a significantly poor OS of patients with digestive cancer (HR = 1.91, 95% CI = 1.38–2.66, P=0.0001), but not lung cancer (HR = 1.83, 95% CI = 0.89–3.76, P=0.010). The RFS of patients with high expression of SNHG15 was shorter than that of patients with low expression of SNHG15 (HR = 2.03, 95% CI = 1.46–2.83, P<0.00001). In addition, high SNHG15 expression level was significantly correlated with later TNM stage (OR = 3.05, 95% CI = 2.31–4.02, P<0.00001), lymphatic metastasis (OR = 3.20, 95% CI = 2.30–4.45, P<0.00001), and distant metastasis (OR = 5.05, 95% CI = 2.15–11.85, P=0.0002). The TCGA verification results were consistent with those observed in our meta-analysis. Conclusion. High expression of the long noncoding RNA SNHG15 in cancer tissue samples predicts an unfavorable prognosis for cancer patients. LncRNA SNHG15 can be used as an adverse prognostic biomarker for cancer patients.

Sign in / Sign up

Export Citation Format

Share Document